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Abstract
This work presents a new mathematical model to depict the effect of obesity on
cancerous tumor growth when chemotherapy as well as immunotherapy have been ad-
ministered. We consider an optimal control problem to destroy the tumor population
and minimize the drug dose over a finite time interval. The constraint is a model includ-
ing tumor cells, immune cells, fat cells, chemotherapeutic and immunotherapeutic drug
concentrations with Caputo time fractional derivative. We investigate the existence and
stability of the equilibrium points namely, tumor free equilibrium and coexisting equilib-
rium, analytically. We discretize the cancer-obesity model using L1-method. Simulation
results of the proposed model are presented to compare three different treatment strate-
gies: chemotherapy, immunotherapy and their combination. In addition, we investigate
the effect of the differentiation order α and the value of the decay rate of the amount
of chemotherapeutic drug to the value of the cost functional. We find out the optimal
treatment schedule in case of chemotherapy and immunotherapy applied.
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1 Introduction
Obesity is associated with increased incidence and mortality of multiple cancers, with risk
ratios correlating directly with body mass index (BMI) in a dose-dependent fashion. Obesity
not only affects cancer incidence and long-term cancer-specific mortality, but also impacts
on survival and recurrence among those diagnosed with cancer. Multiple variables regulate
the obesity-cancer risk equation. Gender and ethnic differences exist; risk ratios for obesity
are significantly higher in men than women for colon cancer incidence. For example, Asians
suffer increased breast cancer risk at lower BMI compared to non-Asians. Obesity is asso-
ciated with a state of chronic systemic inflammation. The link between nutrient excess and
inflammation is rooted in the chemical nature of nutrients, bioenergetic molecules capable
of participating in energy-intensive reactions that are potentially damaging to cells. In ad-
dition, obesity is associated with an increased risk of a number of nutrient deficiencies that
have been implicated in cancer pathogenesis, including vitamin D, selenium, and magne-
sium. To understand the influence of obesity on cancer better, Ku-Carrillo et al. developed
a mathematical model in [14] that incorporates the interaction between the immune system
and adipose cells.
Among evolving treatment modalities, immunotherapy has progressed rapidly into an
auspicious field of medicine. Aim of cancer immunotherapy is to assist the immune sys-
tem to efficiently recognize and attack cancerous cells. This treatment strategy has been
investigated in terms of mathematical models, too. For example, an extended mathematical
model to depict interactions between cancer cells and adaptive immune system in mouse is
proposed in [29] to optimize protocol of immunotherapy with dendritic cell vaccine. Their
model includes tumor cells, natural killers, na¨ıve and mature cytotoxic T cells, regulatory T
cells, na¨ıve and mature helper T cells, dendritic cells and interleukin 2 cytokine. In the study
[5], importance of scheduling immunotherapy is underlined to eradicate and control tumor
population. Moreover, immune competition is analyzed in case of tumor population in [6].
In [31], the effect of chemotherapy and immunotherapy on control of the tumor growth has
been presented. The combined effect of immunotherapy and chemotherapy is investigated
based on optimal control theory in [25].
The aim behind chemotherapy is to eliminate the tumor cells. The cytotoxic drugs,
which have a fast dividing rate, are distributed to different parts of the body through the
blood circulation system. Chemotherapy also affects mitosis rate of some other kinds of
cells that have rapid growth naturally, including hair cells, in an undesirable way [26]. In
several clinical contexts, it is important to minimize, or rather, optimize the amount of
drug(s) used in order to regulate the potentially lethal side effects of chemotherapy in cancer
treatment. Much remarkable work has been done on modeling chemotherapy treatment by
using optimal control theory. For example, optimal control is used to examine the ability
2
of a heterogeneous tumor to counteract the chemotherapeutic drug in [22]. To achieve this
goal, it is underlined that the drug must be injected at the maximum rate [16]. Models for
chemotherapy schedule have been reviewed based on optimal control in [34]. The study [11]
offers a discussion of the prospective application of optimal control theory. Moreover, four
optimal control problems for chemotherapy schedule are investigated in [11] and different
choices of the objective functions in framework of chemotherapy are compared. Combination
of chemotherapy and radiotherapy to eradicate the cancer with metastasis is discussed in
[12]. An adaptive robust control is proposed to adjust the drug dosages with an extended
Kalman filter observer in [32]. An optimal control strategy based on a linear time varying
approximation technique is proposed in [13]. On the other hand, an optimal control prob-
lem (OCP) with a free final-time is solved for tumor-immune interactions with the aim of
minimizing not only the tumor population but also the treatment period in [4]. A model-
free method for chemotherapy based on reinforcement learning is proposed in [24] using the
closed-loop control. Precisely, they develop an optimal controller using Q-learning algorithm
for cancer chemotherapy treatment. In [7], the authors model the chemotherapy treatment
based on optimal control theory and the objective is to minimize the tumor cells while keep-
ing the healthy cells above a fixed level. In the study [35], the interactions between tumor
cells, immune cells, chemotherapeutic and immunotherapeutic dug concentrations are given
by a system of ordinary differential equations. On the other hand, Pillis and Radunskaya
have proposed a system for tumor cells, immune cells, normal cells and chemotherapeutic
drug concentration in [8]. Recently, effect of obesity on cancer growth has been investigated
in [15] by extending the model of Pillis and Radunskaya with fat cells.
Fractional differentiation and integration operators, which are the generalization of classi-
cal integer-order counterparts, are capable of capturing memory effects due to their nonlocal
nature [28, 33, 18]. It is a useful tool to develop suitable models for describing real-world
problems which cannot be expressed by using integer-order differential equations. In the
context of tumor-growth models, we can mention the following papers: A cancer model with
two immune effectors is investigated in terms of Caputo fractional derivative in [3], while a
model for HIV infection of CD4+T cells is generalized with Caputo derivative [30]. Existence
and uniqueness of the solution of a cancer model with Caputo-Fabrizio derivative has been
justified in [9]. For fractional optimal control problems (FOCPs), we can mention the study
[27] where a fractional malaria transmission model is investigated based on optimal control
techniques. In addition, HIV infection is investigated in [10] and West Nile virus model with
Caputo derivative is presented in [37] in terms of Caputo derivative. On the other hand,
an optimal control strategy is proposed for a nonlinear multi-strain tuberculosis model with
Caputo derivatives in [36].
The aim of this paper is to investigate a FOCP governed by a Caputo time fractional
cancer-obesity model. We note that the proposed model is based on the Sharma and
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Samanta’s model [35], which presents the growth/decay of immune and tumor cells when
chemotherapeutic as well as immunotherapeutic drugs have been injected, and Ku-Carrillo et
al.’s work [15], which offers a model for cancer-obesity relation. However, influence of obesity
to cancer growth is not considered in the model in [35]. Our model expresses the intercom-
munication of tumor cells, immune cells, fat cells, chemotherapeutic and immunotherapeutic
drug concentrations in terms of Caputo time fractional derivative. To the best of our knowl-
edge, this is the first study investigating the optimal treatment strategy for a cancerous tu-
mor growth model in terms of a fractional derivative. Moreover, we investigate the existence
and stability of the equilibrium points namely, tumor free equilibrium and coexisting equi-
librium, analytically. We solve the optimal control problem using forward-backward sweep
method after discretizing the fractional differential equation (FDE) applying the so-called
L1 method. We illustrate the contribution of the use of fractional derivatives by solving the
FOCP for different orders of differentiation. In addition, we examine the influence of the
decay rate of amount of chemotherapeutic drug to the value of the cost functional. To sum
up, we find out the optimal treatment schedule in case of chemotherapy and immunotherapy
for a generalized cancer-obesity model.
The rest of the paper is organized as follows: In Sec. 2, we introduce the FOCP governed
by cancer-obesity model and present the optimality system. In Sec. 3, existence of the
equilibrium points and their stability conditions are discussed. In Sec. 4, we explain the
discretization of the FOCP. In Sec. 5, we present some numerical results to compare different
treatment strategies, namely chemotherapy, immunotherapy and their combination. Then,
the paper ends with summary and conclusion.
2 Fractional optimal control problem
In the literature, several fractional derivatives have been defined. One of the mostly used
fractional differentiation operators is Caputo derivative [28]. In this section, we briefly
mention the required definitions and properties of Caputo derivative in order to derive the
optimality system.
Firstly, we define the (left) Caputo fractional differentiation operator for 0 < α < 1 as
in the study [28]:
C
ADαt ϕ(t) =
1
Γ(1− α)
∫ t
A
ϕ′(s)
(t− s)α ds, (2.1)
The corresponding right differentiation operator is defined as
C
t DαBϕ(t) = −
1
Γ(1− α)
∫ B
t
ϕ′(s)
(s− t)α ds. (2.2)
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In addition, the right Riemann-Liouville differentiation operator is written in the form
RL
t DαBϕ(t) = −
d
dt
∫ B
t
ϕ(s)
(s− t)α ds. (2.3)
On the other hand, the fractional integral is given by
AIαt ϕ(t) =
1
Γ(α)
∫ t
A
(t− s)α−1ϕ(s) ds. (2.4)
Lastly, we mention a useful relation between right Caputo and Riemann-Liouville differ-
entiation operators
RL
t DαBϕ(t) = Ct DαBϕ(t) + ϕ(B)
(B − t)−α
Γ(1− α) . (2.5)
In this study, we consider a FOCP governed by a generalized cancer-obesity model. The
model describes the interaction between the state variables, namely tumor cells T (t), im-
mune cells I(t), fat cells F (t), chemotherapeutic and immunotherapeutic drug concentrations
D1(t) and D2(t), respectively. The control variables u1(t) and u2(t) denote the doses of the
chemotherapeutic and immunotherapeutic drugs, respectively. The aim behind the OCP is
to minimize the value of the cost functional J(u1, u2), which is equivalent to minimizing the
tumor population and the drug administered over a finite time interval, where the interac-
tion of tumor cells, immune cells, fat cells and drug concentrations are governed by a time
fractional coupled system of differential equations.
We shortly denote
T := T (t), I := I(t), F := F (t), D1 := D1(t), D2 := D2(t),
and propose the following FOCP
min
u=(u1,u2)∈Uad
J(u1, u2) =
∫ tf
0
(T + ω1u
2
1 + ω2u
2
2) dt (2.6)
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subject to 
C
0 Dαt T = rαT (1− pαT )− ξα1 TI + cα1TF − qα1D1T,
C
0 Dαt I = sα + ρ
αT 2I
hα+T 2+F 2
+ β
αD2I
gα+D2
− ξα2 TI − µαI − qα2D1I,
C
0 Dαt F = dαF (1− αF )− cα2FT − qα3D1F,
C
0 Dαt D1 = u1 − γα1D1,
C
0 Dαt D2 = u2 − γα2D2,
T (0) = T0, I(0) = I0, F (0) = F0, D1(0) = D10, D2(0) = D20,
(2.7)
where the admissible space of controls is given by
Uad = {u = (u1, u2) | u1, u2 are measurable with 0 ≤ u1, u2 ≤ 1, t ∈ [0, tf ]}.
Therefore, the aim is to find the optimal control u∗ = (u∗1, u∗2) ∈ Uad such that J(u∗1, u∗2) =
minu=(u1,u2)∈Uad J(u1, u2) holds.
Now, we proceed with the positivity of the solution of the state equation (2.7). Then,
we obtain the optimality system for the OCP (2.6)-(2.7).
2.1 Existence of positive solutions of the cancer-obesity model
We denote R5+ = {x ∈ R5 | x ≥ 0} and x(t) = (T, I, F,D1, D2)T .
Theorem 2.1. The solution of the FDE (2.7) is unique and it remains in R5+.
Proof. From [19, Theorem 3.1, Remark 3.2], existence of the unique solution to the FDE
(2.7) is proven on (0,∞). Then, we show that the non-negative orthant R5+ is a positively
invariant region. Since,
C
0 Dαt T |T=0 = 0, C0 Dαt I|I=0 = sα ≥ 0, C0 Dαt F |F=0 = 0,
C
0 Dαt D1|D1=0 = u1 ≥ 0, C0 Dαt D2|D2=0 = u2 ≥ 0,
on each line bounding the non-negative orthant, the vector field points into R5+. The solution
will remain in R5+ [23].
2.2 Optimality system
We derive the necessary optimality conditions for the OCP (2.6-2.7).
Theorem 2.2. Given a pair of optimal controls u∗ = (u∗1, u∗2) and the state solutions
(T ∗, I∗, F ∗, D∗1, D∗2) corresponding to (2.7) that minimize objective functional (2.6), there
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exist adjoint variables (λ1, λ2, λ3, λ4, λ5) satisfying
C
t Dαtfλ1 = (rα − 2rαpαT − ξα1 I + cα1F − qα1D1)λ1
+
(
2ραTI(hα+F 2)
(hα+T 2+F 2)2
− ξα2 I
)
λ2 + 1,
C
t Dαtfλ2 = −ξα1 Tλ1 +
(
ραT 2
hα+T 2+F 2
+ β
αD2
gα+D2
− ξα2 T − µα − qα2D1
)
λ2,
C
t Dαtfλ3 = cα1Tλ1 − 2ρ
αT 2IF
(hα+T 2+F 2)2
λ2 + (d
α − 2dααF − cα2T − qα3D1)λ3,
C
t Dαtfλ4 = −qα1 Tλ1 − qα2 Iλ2 − qα3Fλ3 − γα1 λ4,
C
t Dαtfλ5 = β
αgαI
(gα+D2)2
λ2 − γα2 λ5,
(2.8)
with transversality conditions
λ1(tf ) = 0, λ2(tf ) = 0, λ3(tf ) = 0, λ4(tf ) = 0, λ5(tf ) = 0. (2.9)
Moreover, the pair of optimal controls u∗ = (u∗1, u∗2) is represented byu
∗
1 = min
(
max
(
− λ42ω1 , 0
)
, 1
)
,
u∗2 = min
(
max
(
− λ52ω2 , 0
)
, 1
)
.
(2.10)
Proof. Following the proof in [36, Theorem 5.1], we note that existence of a pair of optimal
controls u∗ = (u∗1, u∗2) and the associated state solution (T ∗, I∗, F ∗, D∗1, D∗2) is obtained due
to the convexity of J(u1, u2) with respect to controls and the constraint, which satisfies
Lipschitz property with respect to state variables.
The optimality system can be derived by constructing the Lagrangian as
L(T, I, F,D1, D2, u1, u2, λ1, λ2, λ3, λ4, λ5)
=
∫ tf
0
(
(T + ω1u
2
1 + ω2u
2
2)
− λT1
(
C
0 Dαt T − rαT (1− pαT ) + ξα1 TI − cα1TF + qα1D1T
)
− λT2
(
C
0 Dαt I − sα −
ραT 2I
hα + T 2 + F 2
− β
αD2I
gα +D2
+ ξα2 TI + µ
αI + qα2D1I
)
− λT3
(
C
0 Dαt F − dαF (1− αF ) + cα2FT + qα3D1F
)
− λT4
(
C
0 Dαt D1 − u1 + γα1D1
)
− λT5
(
C
0 Dαt D2 − u2 + γα2D2
))
dt
+ ξ1u1 + ξ2(1− u1) + µ1u2 + µ2(1− u2)
− λ1(0)(T (0)− T0)− λ2(0)(I(0)− I0)− λ3(0)(F (0)− F0)
− λ4(0)(D1(0)−D10)− λ5(0)(D2(0)−D20), (2.11)
7
where λi(t)
′s are the adjoint or co-state variables, ξ1 ≥ 0, ξ2 ≥ 2, µ1 ≥ 0, µ2 ≥ 0 are penalty
multipliers satisfying
ξ1u1 = 0, ξ2(1− u1) = 0, µ1u2 = 0, µ2(1− u2) = 0,
at the optimal u∗ = (u∗1, u∗2). In particular, we present the derivation of the fractional
derivative of the adjoint equation. We apply the method of integration by parts, for example,
to the term λT1 (t)
(
C
0 Dαt T (t)
)
in (2.11) following the study [1, Sec. 2] as
∫ tf
0
λT1 (t)
(
C
0 Dαt T (t)
)
dt =
∫ tf
0
(
R
t Dαtfλ1(t)
)T
T (t) dt, (2.12)
with the condition λ1(tf ) = 0. Then, we proceed as∫ tf
0
λT1 (t)
(
R
t DαtfT (t)
)
dt =
∫ tf
0
(
C
t Dαtfλ1(t)
)T
T (t) dt
=︸︷︷︸
(2.5)
∫ tf
0
(
C
t Dαtfλ1(t)
)T
T (t) dt+
=0︷ ︸︸ ︷
λ1(tf )(tf − t)−α
Γ(1− α)
=
∫ tf
0
(
C
t Dαtfλ1(t)
)T
T (t) dt. (2.13)
Then, we substitute (2.13) into (2.11) and differentiate the resulting equation with respect
to (T, I, F,D1, D2) and (u1, u2) to obtain the adjoint equation (2.8) with final conditions
(2.9) and the gradient equation (2.10), respectively.
3 Equilibrium points and stability analysis
In this section, we will examine the existence of the equilibrium points of the system (2.7),
namely, Tumor Free Equilibrium and Coexisting Equilibrium, and determine the conditions
under which they are stable. Firstly, we fix the doses of chemotherapeutic and immunothera-
peutic drugs as u1(t) = u1 and u2(t) = u2, respectively. Then, we solve the following system
of FDEs for T (t), I(t), F (t), D1(t) and D2(t):
C
0 Dαt T = 0, C0 Dαt I = 0, C0 Dαt F = 0, C0 Dαt D1 = 0, C0 Dαt D2 = 0. (3.1)
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3.1 Tumor free equilibrium
We consider the case that no tumor cells exist, that is, Tˆ = 0. We solve the system (3.1)
and find the tumor-free equilibrium point Eˆ = (0, Iˆ, Fˆ , Dˆ1, Dˆ2) where
Iˆ =
sα(gα + Dˆ2)
(µα + qα2 Dˆ1)(g
α + Dˆ2)− βαDˆ2
,
Fˆ =
1
α
− q
α
3
dαα
Dˆ1, (3.2)
Dˆ1 =
u1
γα1
, Dˆ2 =
u2
γα2
.
The equilibrium point Eˆ exists if Iˆ > 0, Fˆ > 0, Dˆ1 > 0 and Dˆ2 > 0. We note that
Dˆ1 > 0 and Dˆ2 > 0 are automatically satisfied with u1 > 0 and u2 > 0 according to (3.2).
Now, we must assure that Iˆ > 0 and Fˆ > 0 hold. Then, we obtain the following inequalities
Iˆ =
sα(gα + Dˆ2)
(µα + qα2 Dˆ1)(g
α + Dˆ2)− βαDˆ2
=
sαγα1 (γ
α
2 g
α + u2)
µαgαγα1 γ
α
2 + q
α
2 g
αu1γα2 + q
α
2 u1u2 + u2γ
α
1 (µ
α − βα) > 0,
and
Fˆ =
1
α
− q
α
3
dαα
Dˆ1 =
1
α
− q
α
3
dαα
u1
γα1
> 0.
Therefore, we find the following conditions
µαgαγα1 γ
α
2 + q
α
2 g
αu1γ
α
2 + q
α
2 u1u2 + u2γ
α
1 µ
α > u2γ
α
1 β
α, dαγα1 > q
α
3 u1,
so that the equilibrium point Eˆ exists.
Now, we discuss the stability of Eˆ by investigating the signs of the eigenvalues of the
Jacobian associated to the model (2.7).
Theorem 3.1. The equilibrium point Eˆ = (0, Iˆ, Fˆ , Dˆ1, Dˆ2) of the system (2.7) exists under
the condition that
µαgαγα1 γ
α
2 + q
α
2 g
αu1γ
α
2 + q
α
2 u1u2 + u2γ
α
1 µ
α > u2γ
α
1 β
α, dαγα1 > q
α
3 u1. (3.3)
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Moreover, Eˆ = (0, Iˆ, Fˆ , Dˆ1, Dˆ2) is locally asymptotically stable if the following conditions
qα3 u1 < d
αγα1 ,
βαγα1 u2 < (γ
α
1 µ
α + qα2 u1)(γ
α
2 g
α + u2), (3.4)
I∗ >
rα
ξα1
+
cα1
ξα1 
α
−
(
cα1 q
α
3
ξα1 d
αα
+
qα1
ξα1 γ
α
1
)
u1,
together with (3.3) hold.
Proof. The Jacobian of the system (2.7) evaluated at Eˆ = (0, Iˆ, Fˆ , Dˆ1, Dˆ2) is given by
J(E∗) =

ω1 0 0 0 0
ω2 ω3 0 ω4 ω5
ω6 0 ω7 ω8 0
0 0 0 ω9 0
0 0 0 0 ω10
 ,
where
ω1 = r
α − ξα1 Iˆ + cα1 Fˆ − qα1 Dˆ1, ω2 = −ξα2 Iˆ ,
ω3 = −µα − qα2 Dˆ1 + βα
Dˆ2
gα + Dˆ2
, ω4 = −qα2 Iˆ , ω5 =
gαβαIˆ
(gα + Dˆ2)2
,
ω6 = −cα2 Fˆ , ω7 = dα − 2dααFˆ − qα3 Dˆ1,
ω8 = −qα3 Fˆ , ω9 = −γα1 , ω10 = −γα2 .
The eigenvalues of J(Eˆ) are computed as
λ1 = ω9 = −γα1 ,
λ2 = ω10 = −γα2 ,
λ3 = ω3 =
βαu2
γα2 g
α + u2
−
(
µα + qα2
u1
γα1
)
,
λ4 = ω7 =
qα3 u1
γα1
− dα,
λ5 = ω1 = r
α − ξα1 Iˆ + cα1 Fˆ − qα1 Dˆ1
= −ξα1 Iˆ + rα +
cα1
α
−
(
cα1 q
α
3
dαα
+
qα1
γα1
)
u1.
Tumor-free equilibrium point Eˆ is locally asymptotically stable if all eigenvalues λi of
J(Eˆ) are negative. The requirement λ1 < 0 and λ2 < 0 are automatically satisfied. For
λ3, λ4, λ5 to be negative, we reach the conditions in the Eqn. (3.4).
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3.2 Co-existing equilibrium point
In this case, tumor cells coexist, i.e. T 6= 0. By keeping this in mind, we solve (3.1)
for T > 0, I > 0, F > 0, D1 > 0, D2 > 0 to reach the co-existing equilibrium point
E = (T , I, F ,D1, D2).
We find that
D1 =
u1
γα1
, D2 =
u2
γα2
,
F =
1
αdα
(dα − qα3D1 − cα2T ) = k1 + k2T , (3.5)
T =
1
pαrα
(rα − ξα1 I − qα1D1 + cα1F ) = k4 + k5I,
where
k1 =
1
α
− q
α
3
αdα
D1, k2 = − c
α
2
αdα
, k3 =
1
pα
− q
α
1
pαrα
D1,
k4 =
kα3 p
αrα + k1c
α
1
pαrα − cα1k2
=
αdα(kα3 p
αrα + k1c
α
1 )
αdαpαrα + cα1 c
α
2
,
k5 = − ξ
α
1
pαrα − cα1k2
= − 
αdαξα1
αdαpαrα + cα1 c
α
2
.
For simplification purposes, we put
F = k1 + k2(k4 + k5I) = k6 + k7I,
I =
sα(hα + T
2
+ F
2
)(gα +D2)
(µα + αα2 T + q
α
2D1)(h
α + T
2
+ F
2
)(gα +D2)− T 2(ρα(gα +D2) + βαD2)− βαD2(F 2 + hα)
,
where k6 = k1 + k2k4, k7 = k2k5. After arranging the terms, we obtain the following
polynomial in I
m4I
4
+m3I
3
+m2I
2
+m1I +m0 = 0, (3.6)
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where
m4 = θ1k5(k
2
5 + k
2
7),
m3 = θ1(3k4k
2
5 + k4k
2
7 + 2k5k6k7) + θ2k
2
7 + θ3k
2
5,
m2 = θ1(3k
2
4k5 + 2k4k6k7 + k5k
2
6) + θ2(2k6k7) + θ3(2k4k5) + θ4k5 + θ5(k
2
5 + k
2
7),
m1 = θ1(k
3
4 + k4k
2
6) + θ2k
2
6 + θ3k
2
5 + θ4k4 + θ5(2k4k5 + 2k6k7) + θ6,
m0 = θ5(k
2
4 + k
2
6) + θ7,
θ1 = (g
α +D2)ξ
α
2 ,
θ2 = (g
α +D2)(µ
α + qα2D1)− βαD2,
θ3 = (g
α +D2)(µ
α + qα2D1)− (ραgα + ραD2 + βαD2),
θ4 = (g
α +D2)ξ
α
2 h
α,
θ5 = −(gα +D2)sα,
θ6 = (g
α +D2)(h
αµα + qα2 h
αD1)− βαhαD2,
θ7 = −(gα +D2)sαhα.
We observe that
m4 = θ1k5(k
2
5 + k
2
7) < 0,
m0 = θ5(k
2
4 + k
2
6) + θ7 = −(gα +D2)sα(k24 + k26 + hα) < 0.
We obtain following conditions on m1,m2,m3 through the use of Descartes’s rule so that
the Eqn. (3.6) may have non-trivial positive roots:
(1) if m1 < 0, m2 < 0, m3 < 0, then there is no change of sign, so no positive roots of
Eqn. (3.6) exists,
(2) if m1 > 0, m2 < 0, m3 < 0, two or no positive roots of Eqn. (3.6) exist,
(3) if m1 < 0, m2 > 0, m3 < 0, two or no positive roots of Eqn. (3.6) exist,
(4) if m1 > 0, m2 > 0, m3 < 0, two or no positive roots of Eqn. (3.6) exist,
(5) if m1 < 0, m2 < 0, m3 > 0, two or no positive roots of Eqn. (3.6) exist,
(6) if m1 < 0, m2 > 0, m3 > 0, two or no positive roots of Eqn. (3.6) exist,
(7) if m1 > 0, m2 > 0, m3 > 0, two or no positive roots of Eqn. (3.6) exist,
(8) if m1 > 0, m2 < 0, m3 > 0, four or two or no positive roots of Eqn. (3.6) exist.
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Hence, I is not trivially positive if any one of the above seven conditions (2) − (8) is
satisfied. We note that D1 > 0 and D2 > 0 hold due to the non-negative dosage of drugs
u1 > 0 and u2 > 0. Now, we must find the conditions so that T > 0 and F > 0 hold.
According to the equations in (3.5), we find that
F > 0 if k1 + k2T > 0, i.e., T < −k1
k2
=
dαγα1 − qα3 u1
γα1 c
α
2
,
T > 0 if k4 + k5I > 0, i.e., I < −k4
k5
=
k3p
αrα + k1c
α
1
ξα1
.
We summarize the conditions on existence of the equilibrium point E = (T , I, F ,D1, D2)
in the following theorem:
Theorem 3.2. The equilibrium point E = (T , I, F ,D1, D2) of the system (2.7) exists under
the condition that
T <
dαγα1 − qα3 u1
γα1 c
α
2
, I <
k3p
αrα + k1c
α
1
ξα1
, (3.7)
and any one of the seven conditions (2)−(8) above is satisfied, i.e., at least one of m1,m2,m3
is positive.
We proceed with investigation of the stability of the co-existing equilibrium point E =
(T , I, F ,D1, D2). We note that if the eigenvalues, namely λi’s, of the Jacobian matrix
evaluated at E satisfy the condition
|arg(λi)| > αpi
2
, (i = 1, 2, 3, 4, 5), (3.8)
then the system is asymptotically stable at E [21, 2]. In detail, Jacobian matrix of the
system (2.7) evaluated at E = (T , I, F ,D1, D2) is given by
J(E) =

ω1 ω2 ω3 ω4 0
ω5 ω6 ω7 ω8 ω9
ω10 0 ω11 ω12 0
0 0 0 ω13 0
0 0 0 0 ω14
 ,
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where
ω1 = r
α − 2rαpαT − ξα1 I + cα1F − qα1D1, ω2 = −ξα1 T ,
ω3 = c
α
1T , ω4 = −qα1 T , ω5 =
2ραTI(hα + F
2
)
(hα + T
2
+ F
2
)2
− ξ2I,
ω6 =
ραT
2
hα + T
2
+ F
2 +
βαD2
gα +D2
− ξα2 T − µα − qα2D1,
ω7 = − 2ρ
αT
2
IF
(hα + T
2
+ F
2
)2
, ω8 = −qα2 I, ω9 =
βαgαI
(gα +D2)2
,
ω10 = −cα2F , ω11 = dα − 2dααF − cα2T − qα3D1,
ω12 = −qα3F , ω13 = −γα1 , ω14 = −γα2 .
The eigenvalues of J(E) are the roots of the following characteristic polynomial
p(λ) = −(λ− ω13)(λ− ω14) (λ3 + c1λ2 + c2λ+ c3)︸ ︷︷ ︸
:=q(λ)
, (3.9)
where
c1 = (ω1 + ω6 + ω11),
c2 = (−ω1ω6 + ω2ω5 − ω1ω11 + ω3ω10 − ω6ω11), (3.10)
c3 = (ω1ω6ω11 − ω2ω5ω11 + ω2ω7ω10 − ω3ω6ω10).
We can directly deduce that two of the eigenvalues satisfy λ1 = ω13 = −γα1 < 0 and
λ2 = ω14 = −γα2 < 0. Therefore, we proceed with the roots of the polynomial q(λ). We note
that the discriminant of q(λ) is given by
D(q) = 18c1c2c3 + (c1c2)
2 − 4c3c31 − 4c32 − 27c23.
Then, we list the following conditions for the model (2.7) so that the condition (3.8)
holds according to Routh–Hurwitz criteria [2]:
Corollary 3.3. Assume that the conditions of Theorem 3.2 hold so that the co-existing
equilibrium point exists. Then, the equilibrium point E = (T , I, F ,D1, D2) is locally asymp-
totically stable if one of the following conditions holds for polynomial q(λ) which is given as
in (3.9) and coefficients c1, c2, c3 which are given as in (3.10).
(i) If D(q) > 0, then the necessary and sufficient condition for the equilibrium point E to
be locally asymptotically stable is c1 > 0, c3 > 0, c1c2 > c3.
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(ii) If D(q) < 0, c1 ≥ 0, c2 ≥ 0, c3 > 0, then E is locally asymptotically stable for α < 2/3.
(iii) If D(q) < 0, c1 > 0, c2 > 0, c1c2 = c3, then E is locally asymptotically stable.
4 Discretization technique
Let 0 = t0 < t1 < . . . < tN = tf be a subdivision of I = (0, tf ] with constant time step
∆t = T/N . We denote the approximate value of ϕ(t) at t = tj as ϕj .
We present the derivation of the discrete (left/right) Caputo fractional derivative.
4.1 Discrete state equation
L1-method for (left) Caputo fractional derivative has presented in the paper [20, Sec. 3]. We
follow the same idea to obtain
C
0 Dαt ϕ(t)|t=tk =
1
Γ(1− α)
k∑
j=1
ϕj − ϕj−1
∆t
∫ tj
tj−1
(tk − s)−α ds
= B0
k∑
j=1
(ϕj − ϕj−1)
(
δCj,k
)
, (4.1)
where B0 =
−∆t−α
Γ(2−α) , δ
C
j,k = ((k − j)1−α − (k − j + 1)1−α).
We apply the scheme (4.1) to the state equation (2.7). Then, the nonlinear state equation
is linearized by Newton’s method for 1 ≤ k ≤ N and the solution is obtained by solving the
following system iteratively:

δCk,kB0 − J11 −J12 −J13 −J14 0
−J21 δCk,kB0 − J22 −J23 −J24 −J25
−J31 0 δCk,kB0 − J33 −J34 0
0 0 0 δCk,kB0 − J44 0
0 0 0 0 δCk,kB0 − J55


δT
δI
δF
δD1
δD2
 =

R1
R2
R3
R4
R5
 , (4.2)
where
R1 =
C
0 Dαt T (t)|t=tk − (rαTk(1− pαTk)− ξα1 TkIk + cα1TkFk − qα1 (D1)kTk),
R2 =
C
0 Dαt I(t)|t=tk − (sα + ρ
αT 2k Ik
hα+T 2k+F
2
k
+ β
α(D2)kIk
gα+(D2)k
− ξα2 TkIk − µαIk − qα2 (D1)kIk),
R3 =
C
0 Dαt F (t)|t=tk − (dαFk(1− αFk)− cα2FkTk − qα3 (D1)kFk),
R4 =
C
0 Dαt D1(t)|t=tk − ((u1)k − γα1 (D1)k),
R5 =
C
0 Dαt D2(t)|t=tk − ((u2)k − γα2 (D2)k),
(4.3)
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
J11 = r
α − 2rαpαTk − ξα1 Ik + cα1Fk − qα1 (D1)k, J12 = −ξα1 Tk,
J13 = c
α
1Tk, J14 = −qα1 Tk, J21 = 2ρ
αTkIk(h
α+F 2k )
(hα+T 2k+F
2
k )
2 − ξ2Ik,
J22 =
ραT 2k
hα+T 2k+F
2
k
+ β
α(D2)k
gα+(D2)k
− ξα2 Tk − µα − qα2 (D1)k,
J23 = − 2ρ
αT 2k IkFk
(hα+T 2k+F
2
k )
2 , J24 = −qα2 Ik, J25 = β
αgαIk
(gα+(D2)k)2
,
J31 = −cα2Fk, J33 = dα − 2dααFk − cα2Tk − qα3 (D1)k,
J34 = −qα3Fk, J44 = −γα1 , J55 = −γα2 .
(4.4)
4.2 Discrete adjoint equation
The discrete adjoint equation can be derived similarly as
C
t Dαtfϕ(t)|t=tk = −
1
Γ(1− α)
N−1∑
j=k+1
ϕj − ϕj−1
∆t
∫ tj
tj−1
(s− tk)−α ds
= C0
N−1∑
j=k+1
(ϕj−1 − ϕj)
(
ζCj,k
)
, (4.5)
where C0 = −B0, ζCj,k = ((j − k)1−α − (j − k − 1)1−α).
The discrete scheme (4.5) is applied to (2.8) to obtain the following system of equations
for N − 2 ≥ k ≥ 0:

δCk,k+1C0 − J11 −J21 −J31 0 0
−J12 δCk,k+1C0 − J22 0 0 0
−J13 −J23 δCk,k+1C0 − J33 0 0
−J14 −J24 −J34 δCk,k+1C0 − J44 0
0 −J25 0 0 δCk,k+1C0 − J55


(λ1)k+1
(λ2)k+1
(λ3)k+1
(λ4)k+1
(λ5)k+1

=

1 + E0
∑N
j=k+2(λ1)j
(
δCk,j−1 − δCk,j
)
E0
∑N
j=k+2(λ2)j
(
δCk,j−1 − δCk,j
)
E0
∑N
j=k+2(λ3)j
(
δCk,j−1 − δCk,j
)
E0
∑N
j=k+2(λ4)j
(
δCk,j−1 − δCk,j
)
E0
∑N
j=k+2(λ5)j
(
δCk,j−1 − δCk,j
)

. (4.6)
5 Numerical results
In this section, we present some numerical results to compare three different treatment
strategies: chemotherapy, immunotherapy and their combination. In addition, we investigate
the effect of the order of differentiation α and the value of the decay rate of amount of
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chemotherapeutic drug γ1 to the value of the cost functional Jγ1 . We set the values of the
parameters as in Table 1, otherwise stated.
Table 1: Values of the parameters
Parameter Description Value
r Per capita growth rate of tumor cells 0.00431
p Reciprocal carrying capacity of tumor cells 1.02× 10−9
ξ1 Competition term of tumor cells with immune cells 6.41× 10−11
ξ2 Competition term of immune cells with tumor cells 3.42× 10−6
c1 Competition term of fat cells with tumor cells α1
c2 Competition term of fat cells with tumor cells α2
q1 Response of tumor cells to chemotherapeutic drug 0.08
q2 Response of immune cells to immunotherapeutic drug 2× 10−11
q3 Response of fat cells to immunotherapeutic drug q2
s Immune source rate 0.33
ρ Recruitment rate of immune cells by tumor cells 0.0125
h Immune response stimulated by tumor cells 20,200,000
µ Per capita death rate of immune cells 0.204
β Recruitment rate of immune cells by D2 0.125
g Steepness coefficient of the β 20,000,000
d Per capita growth rate of fat cells r/100
 Reciprocal carrying capacity of fat cells p
γ1 Decay rate of D1 0.1
γ2 Decay rate of D2 1
ω1 Weight constant 1
ω2 Weight constant 2
T0 Initial number of tumor cells 2
I0 Initial number of immune cells .1
F0 Initial number of fat cells 1
D10 Initial amount of chemotherapeutic drug .5
D20 Initial amount of immunotherapeutic drug .5
u1 Initial dose of D1 0.5
u2 Initial dose of D2 0.5
tf Final time 120 days
∆t Length of the time step 0.25
We implement the so-called forward-backward sweep method under MATLAB to solve
the OCP (2.6-2.7) [17, Chap. 5]. The algorithm can be summarized as follows:
Before investigating the optimal treatment strategy, we solve the uncontrolled cancer-
obesity model for different values of the order of differentiation α. In Fig. 1, we present the
number of tumor cells, immune cells and fat cells obtained by taking u1 = 0 and u2 = 0
in the FDE (2.7). We observe that the tumor and fat cell population are increasing over
time for different values of α, while the number of immune cells approaches to a fixed value.
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Algorithm 1 Forward-backward sweep method
1: Fix ψ = −1, δ = 0.001.
2: Initiate the control (uold)1, (uold)2, the state xold = {Told, Iold, Fold, (Dold)1, (Dold)2} and
adjoint pold = {(λold)1, (λold)2, (λold)3, (λold)4, (λold)5}.
3: while ψ < 0 do
4: Solve the state equation (2.7) for x = {T, I, F,D1, D2} using T0, I0, F0, D10, D20,
(uold)1, (uold)2 forward in time.
5: Solve the adjoint equation (2.8) for p = {λ1, λ2, λ3, λ4, λ5} using λi(tf ) = 0, x =
{T, I, F,D1, D2} backward in time.
6: Update the control using the gradient equation (2.10) to reach u1, u2.
7: Compute χi = δ‖xi‖− ‖xi− (xold)i‖, υj = δ‖uj‖− ‖uj − (uold)j‖, ρi = δ‖pi‖− ‖pi−
(pold)i‖ and calculate ψ = min{χi, υj , ρi} for i, j ∈ {1, 2, 3, 4, 5}, k ∈ {1, 2}.
8: end while
According to these results, an optimal treatment strategy is required to eliminate tumor
burden as time passes.
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Figure 1: Number of cells for uncontrolled case
5.1 Immunotherapeutic treatment
Firstly, we will examine the contribution of immunotherapy to cure the disease by taking
u1 = 0. In Fig. 2, the number of tumor cells, immune cells and fat cells are depicted. We can
deduce from the figures that immunotherapeutic treatment has no positive effect on tumor
burden, since the tumor cell population cannot be decreased.
In Fig. 3, we depict the immunotherapeutic drug concentration D2(t) and drug dose
u2(t). We notice that immunotherapy has no contribution on tumor population although
drug concentration is increased over time. In addition, the drug dose is quite small which is
not enough to minimize the tumor population.
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Figure 2: Number of cells for immunotherapy
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Figure 3: Amount & dose of immunotherapeutic drug
5.2 Chemotherapeutic treatment
We proceed with chemotherapeutic treatment where u2 = 0. In Fig. 4, tumor, immune
and fat population are presented. We immediately see that tumor population is successfully
minimized over time despite of increasing number of fat cells in the system, while the immune
population is not destroyed.
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Figure 4: Number of cells for chemotherapy
We investigate the effect of the order α and the decay rate γ1 to the value of the cost
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functional Jγ1 and we present the results in Table 2. Firstly, we notice that the value of Jγ1
decreases as we increase α. Moreover, a smaller value of Jγ1 is measured for smaller values
of the decay rate γ1, since more drug is contained in the system. A FOCP with a smaller
value of α can be regarded as a model containing information about history, so the system
with a small value of α is more vulnerable to environmental changes.
Table 2: Values of the cost functional Jγ1 for chemotherapy
α Jγ1=0.1 Jγ1=0.5 Jγ1=0.9
0.8 88.0784 135.3614 177.9395
0.9 81.3347 117.0319 156.5642
0.95 79.3366 110.2287 147.9902
In Fig. 5, we present the chemotherapeutic drug concentration D1(t) and drug dose u1(t).
We observe that the reverse relation between the order α and the value of Jγ1 is revealed,
since drug concentration gets higher as α increases. Thus, more tumor cells are destroyed
due to higher drug concentration. On the other hand, the drug dose decreases as time passes,
which means that the functional Jγ1 has been minimized successfully over time.
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Figure 5: Amount & dose of chemotherapeutic drug
5.3 Combination of chemotherapeutic & immunotherapeutic treatment
We proceed with the combination of chemotherapeutic and immunotherapeutic treatment
where u1 6= 0 and u2 6= 0. In Fig. 6, the number of tumor cells, immune cells and fat cells
are depicted. We observe that the tumor population is decreased. There is not a visible
difference between chemotherapeutic treatment and combined therapy. Therefore, we will
compute Jγ1 to assess the contribution of combined therapy.
In Table 3, we present the values of Jγ1 for different values of α and γ1. As we increase γ1,
Jγ1 decreases; while the fractional order has a reverse effect. When we compare Table 3 with
Table 2, we deduce that combined therapy gives much better results than chemotherapy.
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Figure 6: Number of cells for combined chemotherapy & immunotherapy
On account of a stronger immune system, immune cells fight with tumor cells much better
and tumor population shrinks in size. We think that a system including memory effect,
which corresponds to the use of fractional order derivatives in the underlying model, can
be regarded as a model associated with a population which can correctly adjust itself to
environmental changes and which can rebound itself on account of previous experiences.
Table 3: Values of the cost functional Jγ1 for chemotherapy & immunotherapy
α Jγ1=0.1 Jγ1=0.5 Jγ1=0.9
0.8 36.7257 70.6701 95.7243
0.9 28.1606 53.7762 77.6948
0.95 24.9350 45.7107 69.0309
In Fig. 7, we present the drug concentration and dose for chemotherapeutic and im-
munotherapeutic treatment. As time passes, drug concentrations D1(t) and D2(t) decreases.
Otherwise, it might be harmful for healthy and immune cells. Dose of drugs u1(t) and u2(t)
lies within the admissible set and they decrease over time. Although the control u2 seems
too small, immunotherapeutic treatment leads Jγ1 to decrease more than 50%.
6 Summary and conclusion
In this study, we investigate the optimal treatment strategy for a cancer-obesity model. In-
teractions between tumor cells, immune cells, fat cells, chemotherapeutic and immunothera-
peutic drug concentrations are modeled with Caputo time fractional derivative. The aim is
to find a pair of controls, which correspond to drug dose, to minimize the number of tumor
cells over a finite time period, while finding the minimum drug dose injected to the system.
We compare immunotherapy, chemotherapy and their combination to treat the tumor. We
find out that mixed immune-chemotherapy gives the smallest value of the cost-functional J .
Moreover, we notice that the values of J decreases as we increase the order of differentia-
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Figure 7: Amount of drug and drug control
tion α. We think that a system including memory effect, which corresponds to the use of
fractional order derivatives in the underlying model, can be regarded as a model associated
with a population which can correctly adjust itself to environmental changes and which can
rebound itself on account of previous experiences. As a future work, we will investigate the
optimal treatment strategy through the use a fractional derivative with nonsingular kernel.
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